Raymond James Financial’s Definium Therapeutics DFTX Stock Holding History

Raymond James Financial’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Sell	22,401 -1,312	-6%	-$32.4K	﹤0.01%	3960
2026 Q1	$448K	Buy	23,713 +2,592	+12%	+$44K	﹤0.01%	4421
2025 Q4	$283K	Buy	21,121 +3,329	+19%	+$41.2K	﹤0.01%	4612
2025 Q3	$210K	Buy	17,792 +763	+4%	+$7.12K	﹤0.01%	4602
2025 Q2	$111K	Sell	17,029 -1,450	-8%	-$9.54K	﹤0.01%	4826
2025 Q1	$108K	Buy	18,479 +2,475	+15%	+$17.7K	﹤0.01%	4536
2024 Q4	$111K	Buy	+16,004	New	+$110K	﹤0.01%	4512

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Raymond James Financial's DFTX Position: Q2 2026 in Review

Raymond James Financial reduced its Definium Therapeutics (DFTX) stake by 5.5% in Q2 2026, selling an estimated $32.4K and leaving 22,401 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3960.

Raymond James Financial first reported a position in DFTX in Q4 2024 and has held it in 7 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Raymond James Financial held 22,401 shares of Definium Therapeutics worth $1.05M as of Q2 2026.
Raymond James Financial sold 1,312 Definium Therapeutics shares in Q2 2026, an estimated $32.4K.
Definium Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3960 holding.
Raymond James Financial first reported a position in Definium Therapeutics in Q4 2024 and has held it in 7 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.